Barrera Jose E, Miller Mark E, Said Sherif, Jafek Bruce W, Campana John P, Shroyer Kenneth R
Department of Otolaryngology-Head and Neck Surgery, University of Colorado Health Sciences Center, Denver, 80262, USA.
Laryngoscope. 2003 May;113(5):892-6. doi: 10.1097/00005537-200305000-00022.
The incidence of occult nodal metastases associated with head and neck squamous cell carcinoma (HNSCC) and the clinical significance of nodal micrometastases by cytokeratin immunohistochemical analysis are examined.
In all, 1012 lymph nodes from 50 patients treated between 1992 and 2001 at the University of Colorado Health Sciences Center (Denver, CO) were evaluated retrospectively for micrometastases.
Serial sectioning in 5-to 6-microm interval specimens stained either with hematoxylin and eosin (H&E) or immunostaining for cytokeratins using the monoclonal antibody cocktail AE1/AE3 was performed in 21 N0, 11 N1, and 14 N2 patient cases. Cases that showed scattered cells with suspect staining qualities but without morphological features consistent with HNSCC were further evaluated by epithelial membrane antigen (EMA) immunohistochemical analysis.
H&E-stained and cytokeratin-stained sections revealed occult nodal micrometastases in 3.8% of N0 and 5% of N1 cases. Overall, 26 micrometastases were identified in N0 and N1 patients, causing 29% of N0 patients and 45% of N1 patients to be upstaged. Cytokeratin immunostaining detected micrometastases in eight cases that were negative on H&E serial sectioning. Serial sectioning by H&E alone identified three additional micrometastases. Negative EMA immunostaining confirmed the absence of malignant cells in lymph node sections that were equivocal on cytokeratin staining.
The use of serial sectioning with H&E and cytokeratin immunohistochemical analysis increases the detection of micrometastases that are often elusive by routine processing in patients with HNSCC. Improved methods of detecting micrometastases may provide a basis for improved planning of postoperative therapy for patients already at risk for tumor recurrence.
研究头颈部鳞状细胞癌(HNSCC)隐匿性淋巴结转移的发生率,以及通过细胞角蛋白免疫组化分析检测淋巴结微转移的临床意义。
回顾性评估1992年至2001年在科罗拉多大学健康科学中心(丹佛,科罗拉多州)接受治疗的50例患者的1012个淋巴结,以检测微转移。
对21例N0、11例N1和14例N2患者的病例进行连续切片,切片间隔为5至6微米,分别用苏木精和伊红(H&E)染色或使用单克隆抗体混合物AE1/AE3进行细胞角蛋白免疫染色。对那些显示散在细胞且染色质量可疑但无符合HNSCC形态特征的病例,进一步通过上皮膜抗原(EMA)免疫组化分析进行评估。
H&E染色和细胞角蛋白染色切片显示,3.8%的N0病例和5%的N1病例存在隐匿性淋巴结微转移。总体而言,在N0和N1患者中发现了26个微转移灶,导致29%的N0患者和45%的N1患者分期上调。细胞角蛋白免疫染色在8例H&E连续切片为阴性的病例中检测到了微转移灶。仅通过H&E连续切片又发现了另外三个微转移灶。EMA免疫染色阴性证实了细胞角蛋白染色可疑的淋巴结切片中不存在恶性细胞。
使用H&E连续切片和细胞角蛋白免疫组化分析可提高对HNSCC患者中常规处理时常难以发现的微转移灶的检测率。改进的微转移灶检测方法可能为改善对已有肿瘤复发风险患者的术后治疗规划提供依据。